QURE AMT-130: 75% Huntington's Slowing at $2.78B

Huntington’s disease is a death sentence written in your DNA. One bad copy of the huntingtin gene guarantees progressive motor decline, cognitive deterioration, and death, usually within 15 to 20 years of onset. There are zero approved disease-modifying therapies. The global patient population is roughly 80,000. uniQure (QURE) closed at $40.07 with a $2.78 billion market cap, and it is the only company with a gene therapy in regulatory pre-submission for this disease. The question is whether 12 patients is enough evidence for the FDA.

The disease: genetic, fatal, untreatable

Huntington’s is an autosomal dominant CAG repeat disorder. A mutation in the HTT gene produces abnormal huntingtin protein that aggregates in the brain, destroying neurons in the striatum first, then spreading. Symptoms typically appear between ages 30 and 50. Roughly 75,000 people have manifest Huntington’s in the US, EU, and UK, with hundreds of thousands more at genetic risk. The disease progresses relentlessly: loss of motor control, cognitive decline, psychiatric symptoms, and death. Current treatments address symptoms only. No drug has ever slowed disease progression.

The science: AMT-130 and AAV5 intrastriatal delivery

AMT-130 uses an AAV5 vector to deliver an artificial microRNA (miHTT) that silences huntingtin protein production at the source. The AAV5 vector, compared to lentivirus in our gene therapy vectors explainer, is delivered via MRI-guided, convection-enhanced stereotactic neurosurgery directly into the striatum (caudate and putamen). This is a one-time administration. The microRNA targets both the full-length huntingtin protein and the highly toxic exon-1 isoform, suppressing production non-selectively across both mutant and wild-type alleles.

The delivery is what makes this risky. Systemic AAV gene therapies inject into the bloodstream. AMT-130 requires neurosurgery: drilling into the skull, threading catheters into the brain, and infusing the vector via convection-enhanced delivery. This is not a pill. It is not even an injection. It is brain surgery. The manufacturing complexity of AAV5 at commercial scale adds another layer of risk. For more on clinical trial phases, this program sits in a regulatory gray zone between Phase 1/2 and registrational.

The trial data: 12 patients, 75% disease slowing

The registrational Phase 1/2 study (NCT04120493) randomized 26 patients with early manifest Huntington’s to treatment (6 low dose, 10 high dose) or sham surgery (10), with 4 controls crossing over. At 36 months, the high-dose group showed:

A statistically significant 75% slowing of disease progression measured by cUHDRS (p=0.003), with treated patients showing a mean change of -0.38 from baseline versus -1.52 for the propensity score-matched external control from the Enroll-HD natural history dataset. A 60% slowing on the TFC functional capacity scale (p=0.033). Favorable trends on cognitive measures including an 88% slowing on SDMT (p=0.057) and a 113% slowing on SWRT (p=0.0021). CSF neurofilament light chain (NfL), a biomarker of neurodegeneration, was 8.2% below baseline at 36 months, suggesting reduced neuronal damage. The full registrational Phase 1/2 data was published in September 2025 and presented at the HD community meeting.

The critical caveat: only 12 high-dose patients had reached 36 months of follow-up at the data cutoff. This is a 12-patient efficacy dataset compared to an external control, not a randomized control arm. The p-values are nominal. The FDA initially pushed back hard in November 2025, stating that the Phase 1/2 data were insufficient to support a marketing application. But in June 2026, after a Type B meeting, the FDA reversed course and agreed the 3-year data can serve as the primary basis for an accelerated approval BLA submission in Q3 2026.

The competitive picture

No other gene therapy for Huntington’s is this close to regulatory submission. The competitive pipeline includes Roche’s RG6042 (antisense oligonucleotide), PTC Therapeutics’ PTC518 (oral splicing modifier), and Alnylam’s ALN-HTT02 (RNAi), all in earlier stages of development. uniQure has a multi-year lead. If AMT-130 is approved under the accelerated approval pathway, it becomes the first disease-modifying therapy for Huntington’s and the first gene therapy delivered directly to the brain for a neurodegenerative disease.

For broader context, we track AMT-130 alongside other gene therapy catalysts and neuroscience biotech catalysts in our sector roundups. The CRISPR gene editing space is developing separately for other indications.

Valuation: $2.78B for a 12-patient dataset

QURE at $2.78B is a pre-revenue gene therapy company with one asset in regulatory pre-submission. The comp comparison: uniQure is closest to a pure-play gene therapy company with a neurological disease focus. Sarepta Therapeutics (SRPT) trades at roughly $1.7B with $2.2B in annual revenue and multiple approved DMD products. uniQure at $2.78B with zero revenue is valued 1.6x higher than a revenue-generating gene therapy company. That premium reflects the novelty of the first disease-modifying Huntington’s therapy and the Breakthrough Therapy/RMAT designations.

The Huntington’s disease market was valued at roughly $320 million in 2025, with industry analysts projecting 14% CAGR through 2036. If AMT-130 is approved at a gene therapy price point of $500,000 to $1 million per patient, in line with other one-time gene therapies, and the addressable US population is roughly 30,000 diagnosed patients, peak revenue could reach $1.5B to $3B. Against a $2.78B market cap, that is a compelling risk-reward if approval comes through.

Risks: surgery, sample size, and the external control

Three specific risks define this bet. First, the surgical delivery complexity limits the addressable market. Not every neurology center can perform MRI-guided stereotactic neurosurgery. The rollout will be slow and center-dependent. Manufacturing AAV5 at commercial scale adds further complexity: the vector must be produced consistently at high titer, and intracranial delivery requires specialized neurosurgical training that limits the number of treating sites to 20 to 30 centers initially.

Second, the 12-patient dataset is small. The FDA accepted it under accelerated approval, but a confirmatory trial will be required post-approval, and that trial needs to verify clinical benefit in a larger population. The confirmatory study design is still being negotiated with the FDA. A sham-surgery control arm is ethically and practically difficult in Huntington’s, where patients and families are desperate for any treatment. The FDA has indicated openness to a confirmatory trial using standard-of-care comparators rather than sham neurosurgery, which would make enrollment easier.

Third, the external control arm is a propensity score-matched dataset from Enroll-HD, not a randomized control. The FDA’s initial rejection in November 2025 shows the agency has concerns about this methodology. The June 2026 reversal suggests those concerns were addressed, but the review will scrutinize the matching methodology. If the propensity score matching is challenged during review, the entire efficacy argument rests on a fragile foundation.

Verdict: buy with position-sized risk

QURE at $2.78B is the purest play on a Huntington’s disease-modifying therapy. The 75% disease slowing at 36 months is the most compelling data in the field. The FDA’s accelerated approval pathway agreement in June 2026 de-risked the regulatory path materially after the November 2025 rejection. The BLA submission in Q3 2026 is the next catalyst, and if accepted with Priority Review, a PDUFA date in Q1 or Q2 2027 follows.

The position-sizing question: a 12-patient dataset compared to an external control is not a Phase 3 randomized trial. The approval probability is real but not certain. The stock will move 50%+ on BLA acceptance or rejection. If the FDA accepts the BLA, the stock re-rates toward the $4-5B range on the optionality of a first-in-class approval. If the FDA requests a Phase 3 trial before submission, the stock drops 30%+ on the extended timeline.

The case for buying QURE ahead of the Q3 BLA submission is the 75% disease slowing at 36 months, the only positive Phase data in Huntington’s to date, with a position sized for binary risk. The FDA has agreed the data is sufficient for accelerated approval. The risk is real, but the reward is a first-in-disease gene therapy at a $2.78B market cap. That is a bet worth taking.